1.Allogenic bone marrow transplantation in rabbit.
Kir Young KIM ; Duk Hee KIM ; Young Mo SHON ; Kwan Sub CHUNG ; Hong Jin KIM ; Duk Jin YUN
Journal of the Korean Pediatric Society 1982;25(9):867-879
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
2.Bone Marrow Transplantation.
Journal of the Korean Pediatric Society 1987;30(10):1065-1070
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
3.Bone Marrow Transplantation.
The Korean Journal of Critical Care Medicine 2001;16(1):17-22
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
4.Unusual complications after allogeneic bone marrow transplantation.
Hyun Bok HAN ; Jong Wook LEE ; Chi Wha HAN ; Woo Sung MIN ; Chong Won PARK ; Choon Choo KIM ; Dong Jip KIM
Korean Journal of Hematology 1991;26(2):339-347
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
5.Bone marrow transplantation during 1995-2000
Journal of Vietnamese Medicine 2000;248(6):20-34
The bone marrow transplantation is a most modern technique and applied in Vietnam to treat the malignant hematological diseases. This paper introduced the bone marrow heterotransplantation and the autologous peripheral blood stem cell transplantation. 3 patients (1 male; 2 female) received transplantation (bone marrow fluid was extracted from patient’s brothers) for the treatment of the chronic myeloid leukemia and severe thalassemia and 17 patients received the autologous peripheral blood stem cell transplantation for treatment of acute myeloid leukemia, chronic myeloid leukemia, acute lyphoid leukemia and lymphoma. The results have shown that the longest survival duration was 42 months after the autologous peripheral blood stem cell transplantation. The patients had a normal life such as learning, working and social activities. After 2 months of transplantation, the average disease free duration of 10 patients with AML and 6 patients with ALL were 27 months, and 30-40 months, respectively. This was an great encouragement.
Bone Marrow Transplantation
;
Bone marrow
;
Bone and bones
6.Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia.
Hee Jung SOHN ; Gunn Doo JANG ; Young Rok SHIN ; Hye Jin KANG ; Sarah PARK ; Eun Kyung KIM ; Gyeong Won LEE ; Jae Lyun LEE ; Min Hee RYU ; Seong Jun CHOI ; Je Hwan LEE ; Sung Bae KIM ; Sang We KIM ; Kyoo Hyung LEE ; Jung Shin LEE ; Woo Kun KIM ; Cheolwon SUH
Korean Journal of Hematology 2003;38(1):1-7
BACKGROUND: We performed this study to compare response rate and survival according to treatment modalities, such as allogeneic bone marrow transplantation (BMT), immunosuppressive therapy (IS) and androgen therapy in patients with aplastic anemia (AA). METHODS: Medical records of one hundred and thirty-seven patients who diagnosed with aplastic anemia at the Asan Medical Center from September 1989 to December 2000 were retrospectively analyzed. RESULTS: Forty-one patients received supportive care only. Ninety-five out of 96 treated patients were evaluable for response. In severe AA group (N=79), the response rate according to treatment modalities was 25.0% in the androgen group (N=4), 30.3% in the ALG or ATG group (N=33), 25.0% in the cyclosporine (CSA) group (N=8), 44.4% in the ATG plus CSA group (N=9), and 73.8% in the BMT group (N=23) (P<0.001). Five- and 10-year survival of overall patients was 67.5% and 50.9%, respectively. Ten-year survival according to disease severity was 42.3% in severe AA group and 75.8% in non-severe AA group (P=0.0043). Five- year survival according to treatment modalities in patients with severe AA was 75.0% in the androgen group, 49.0% in the ALG or ATG group, 75.0% in the CSA group, and 88.9% in the ATG plus CSA group. Five-year survival was 82.6% in the BMT group and 57.7% in the IS group (P=0.0259). CONCLUSION: This study showes that BMT resulted in significantly better response rate and overall survival compared to IS in patients with severe AA.
Bone Marrow Transplantation
7.Bone marrow Transplantation in Children.
Journal of the Korean Pediatric Society 1996;39(9):1193-1200
No abstract available.
Bone Marrow Transplantation*
;
Bone Marrow*
;
Child*
;
Humans
8.Revisiting anemia afer ABO-mismatched allogeneic bone marrow transplantation.
Gyu Taek LIM ; Dong Wook KIM ; Jong Youl JIN ; Jong Wook LEE ; Chi Wha HAN ; Woo Sung MIN ; Chong Won PARK ; Choon Choo KIM ; Dog Jip KIM
Korean Journal of Hematology 1991;26(1):13-21
No abstract available.
Anemia*
;
Bone Marrow Transplantation*
;
Bone Marrow*
9.The blood transfusion in the bone marrow transplantation
Journal of Vietnamese Medicine 1998;225(9, 10):40-45
The blood transfusion is necessary while the donor’s marrow has not been growed yet. The transfused blood products must assure completely the safety principles for disease transmission, the blood products is not infected the MCV and removed the leucocyte usually transfused after 4- 12 weeks of transplantation with the suitable dosage for individuals. Condensed platalet is transfused after 6-12 weeks of transplantation. It should maintain the amount of thrombocyte in the peripheral blood within 50-100x109/lit, the dose is different from one patient to another.
Blood transfusion
;
Bone marrow
;
Transplantation
10.Cord blood as a valuable source of hemopoietic stem cell for bone marrow transplantation
Journal of Vietnamese Medicine 1999;233(2):19-21
We studied on hematological parameters, lymphocytes distribution and stem cell (CD34 positive) count from cord blood of 43 healthy newborn at obstetrics department, Bach Mai hospital. The result showed that, stem cell count of cord blood is high (16.2% of nucleated cell, equal to 2.4+/- 0.3 G/l). this will be useful to allegoric stem cell transplantation. However, relatively high count of white cell (especially T lymphocyte) can be considerable to procedure and transplant result, free of graft versus host disease.
Fetal Blood
;
Bone Marrow Transplantation
Result Analysis
Print
Save
E-mail